212 related articles for article (PubMed ID: 36550421)
41. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.
Sato T; Morita S; Bando H; Sato S; Ikeda T; Emi K
Middle East Afr J Ophthalmol; 2013; 20(1):51-5. PubMed ID: 23580852
[TBL] [Abstract][Full Text] [Related]
42. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
43. Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage.
Ratnarajan G; Mellington F; Saldanha M; de Silva SR; Benjamin L
Eye (Lond); 2011 Jun; 25(6):704-8; quiz 709. PubMed ID: 21494282
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of intravitreal triamcinolone acetonide for eyes with postvitrectomy diabetic vitreous hemorrhage.
Lee SY; Lee HG; Chung HW; Yoon YH; Kim JG
Korean J Ophthalmol; 2007 Dec; 21(4):208-12. PubMed ID: 18063884
[TBL] [Abstract][Full Text] [Related]
45. Recovery of visual field defects following vitrectomy for proliferative diabetic retinopathy: A case report.
Lo KJ; Yang JH; Cheng HC; Chang HY; Lin TC
Medicine (Baltimore); 2021 Dec; 100(48):e27793. PubMed ID: 35049178
[TBL] [Abstract][Full Text] [Related]
46. Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy.
Yeh PT; Yang CH; Yang CM
Acta Ophthalmol; 2011 Nov; 89(7):634-40. PubMed ID: 20064118
[TBL] [Abstract][Full Text] [Related]
47. Endodiathermy plus photocoagulation as treatment of sclerotomy site vascularization secondary to pars plana vitrectomy for proliferative diabetic retinopathy.
Nadal J; Carreras E; Canut MI
Retina; 2012 Jul; 32(7):1310-5. PubMed ID: 22466471
[TBL] [Abstract][Full Text] [Related]
48. The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage.
Li S; Yang Y; Zou J; Zeng J; Ding C
BMC Ophthalmol; 2022 Feb; 22(1):63. PubMed ID: 35139812
[TBL] [Abstract][Full Text] [Related]
49. Comparison of surgical procedures for vitreous surgery in diabetic macular edema.
Shiba T; Kamura Y; Yagi F; Sato Y
Jpn J Ophthalmol; 2009 Mar; 53(2):120-124. PubMed ID: 19333695
[TBL] [Abstract][Full Text] [Related]
50. Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy.
Yan H; Cui J; Lu Y; Yu J; Chen S; Xu Y
Curr Eye Res; 2010 Apr; 35(4):308-13. PubMed ID: 20373898
[TBL] [Abstract][Full Text] [Related]
51. Diode laser, vitrectomy and intravitreal triamcinolone. A comparative study for the treatment of diffuse non tractional diabetic macular edema.
Parolini B; Panozzo G; Gusson E; Pinackatt S; Bertoldo G; Rottini S; Pignatto S
Semin Ophthalmol; 2004; 19(1-2):1-12. PubMed ID: 15658006
[TBL] [Abstract][Full Text] [Related]
52. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy.
Chen HJ; Wang CG; Dou HL; Feng XF; Xu YM; Ma ZZ
Ann Palliat Med; 2020 Jan; 9(1):82-89. PubMed ID: 32005066
[TBL] [Abstract][Full Text] [Related]
53. Intraocular pressure after intravitreal injection of triamcinolone acetonide following vitrectomy for macular edema.
Yamashita T; Uemura A; Kita H; Sakamoto T
J Glaucoma; 2007 Mar; 16(2):220-4. PubMed ID: 17473734
[TBL] [Abstract][Full Text] [Related]
54. PERSISTENT OVERPRODUCTION OF INTRAOCULAR VASCULAR ENDOTHELIAL GROWTH FACTOR AS A CAUSE OF LATE VITREOUS HEMORRHAGE AFTER VITRECTOMY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
Wakabayashi Y; Usui Y; Tsubota K; Ueda S; Umazume K; Muramatsu D; Goto H
Retina; 2017 Dec; 37(12):2317-2325. PubMed ID: 28098727
[TBL] [Abstract][Full Text] [Related]
55. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
[TBL] [Abstract][Full Text] [Related]
56. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
Yang CS; Hung KC; Huang YM; Hsu WM
J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
[TBL] [Abstract][Full Text] [Related]
57. Complications, Compliance, and 3-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage.
Kasetty VM; Starnes DC; Sood N; Qin LG; Moses MM; Frazier HK; Singh H; Marcus DM
Ophthalmic Surg Lasers Imaging Retina; 2023 Feb; 54(2):89-96. PubMed ID: 36780633
[TBL] [Abstract][Full Text] [Related]
58. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: an ultrasound biomicroscopy study.
Yeh PT; Yang CM; Yang CH; Huang JS
Ophthalmology; 2005 Dec; 112(12):2095-102. PubMed ID: 16225926
[TBL] [Abstract][Full Text] [Related]
59. Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment.
Yeung L; Liu L; Wu WC; Kuo YH; Chao AN; Chen KJ; Yang KJ; Chen TL; Lai CC
Acta Ophthalmol; 2010 Sep; 88(6):635-40. PubMed ID: 19432872
[TBL] [Abstract][Full Text] [Related]
60. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema.
Avitabile T; Longo A; Reibaldi A
Am J Ophthalmol; 2005 Oct; 140(4):695-702. PubMed ID: 16226521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]